Zhejiang Sunflower Light Energy Market Cap ($612.17 Million)
Market Cap & Net Worth: Zhejiang Sunflower Light Energy (300111)
Zhejiang Sunflower Light Energy market cap. Zhejiang Sunflower Light Energy (SHE:300111) has a market capitalization of $612.17 Million (CN¥4.18 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #10921 globally and #2956 in its home market, demonstrating a 3.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Sunflower Light Energy's stock price CN¥3.25 by its total outstanding shares 1287210714 (1.29 Billion). Also see cash flow conversion of Zhejiang Sunflower Light Energy for how efficiently the company converts equity into cash flow.
Zhejiang Sunflower Light Energy Market Cap History (2015–2026)
Zhejiang Sunflower Light Energy market cap history from 2015 to 2026. Data shows change from $1.24 Billion to $612.17 Million (-5.45% CAGR). Check Zhejiang Sunflower Light Energy stock quote for real-time trading data and today's change.
Zhejiang Sunflower Light Energy Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Sunflower Light Energy's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Zhejiang Sunflower Light Energy growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.25x
Zhejiang Sunflower Light Energy's market cap is 4.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $992.65 Million | $1.60 Billion | $30.64 Million | 0.62x | 32.39x |
| 2017 | $676.21 Million | $1.53 Billion | $23.70 Million | 0.44x | 28.53x |
| 2018 | $378.60 Million | $900.22 Million | -$1.12 Billion | 0.42x | N/A |
| 2019 | $440.76 Million | $836.61 Million | -$114.93 Million | 0.53x | N/A |
| 2020 | $602.75 Million | $286.96 Million | $55.87 Million | 2.10x | 10.79x |
| 2021 | $593.33 Million | $297.29 Million | $53.42 Million | 2.00x | 11.11x |
| 2022 | $614.05 Million | $335.86 Million | -$1.14 Million | 1.83x | N/A |
| 2023 | $572.61 Million | $338.42 Million | $21.75 Million | 1.69x | 26.33x |
| 2024 | $610.28 Million | $330.37 Million | $7.83 Million | 1.85x | 77.97x |
| 2025 | $1.15 Billion | $271.53 Million | -$4.38 Million | 4.25x | N/A |
Competitor Companies of 300111 by Market Capitalization
Companies near Zhejiang Sunflower Light Energy in the global market cap rankings as of November 5, 2026. Also see Zhejiang Sunflower Light Energy assets under control for a full breakdown of the balance sheet.
Key companies related to Zhejiang Sunflower Light Energy by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Zhejiang Sunflower Light Energy (2015–2026)
Market capitalization of Zhejiang Sunflower Light Energy from 2015 to today. Between 2015 and today, Zhejiang Sunflower Light Energy's market cap moved from $1.24 Billion to $ 612.17 Million, with a yearly change of -5.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥612.17 Million | -46.98% |
| 2025 | CN¥1.15 Billion | +89.20% |
| 2024 | CN¥610.28 Million | +6.58% |
| 2023 | CN¥572.61 Million | -6.75% |
| 2022 | CN¥614.05 Million | +3.49% |
| 2021 | CN¥593.33 Million | -1.56% |
| 2020 | CN¥602.75 Million | +36.75% |
| 2019 | CN¥440.76 Million | +16.42% |
| 2018 | CN¥378.60 Million | -44.01% |
| 2017 | CN¥676.21 Million | -31.88% |
| 2016 | CN¥992.65 Million | -19.91% |
| 2015 | CN¥1.24 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Zhejiang Sunflower Light Energy was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $612.17 Million USD |
| MoneyControl | $612.17 Million USD |
| MarketWatch | $612.17 Million USD |
| marketcap.company | $612.17 Million USD |
| Reuters | $612.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Sunflower Light Energy
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pne… Read more